These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12433825)

  • 21. Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model.
    Lundquist P; Lööf J; Fagerholm U; Sjögren I; Johansson J; Briem S; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):459-68. PubMed ID: 24396143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.
    Ito K; Houston JB
    Pharm Res; 2005 Jan; 22(1):103-12. PubMed ID: 15771236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations.
    Jones HM; Houston JB
    Drug Metab Dispos; 2004 Sep; 32(9):973-82. PubMed ID: 15319339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The binding of drugs to hepatocytes and its relationship to physicochemical properties.
    Austin RP; Barton P; Mohmed S; Riley RJ
    Drug Metab Dispos; 2005 Mar; 33(3):419-25. PubMed ID: 15616151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma.
    Skaggs SM; Foti RS; Fisher MB
    J Pharmacol Toxicol Methods; 2006; 53(3):284-90. PubMed ID: 16300971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of metabolic stability screening: comparison of in vitro and in vivo clearance.
    Clarke SE; Jeffrey P
    Xenobiotica; 2001; 31(8-9):591-8. PubMed ID: 11569527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.
    Kilford PJ; Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2008 Jul; 36(7):1194-7. PubMed ID: 18411401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data.
    Kalvass JC; Tess DA; Giragossian C; Linhares MC; Maurer TS
    Drug Metab Dispos; 2001 Oct; 29(10):1332-6. PubMed ID: 11560877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.
    Carlile DJ; Stevens AJ; Ashforth EI; Waghela D; Houston JB
    Drug Metab Dispos; 1998 Mar; 26(3):216-21. PubMed ID: 9492383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prediction of benzo[a]pyrene clearance by rat liver and lung from enzyme kinetic data.
    Wiersma DA; Roth RA
    Mol Pharmacol; 1983 Sep; 24(2):300-8. PubMed ID: 6310365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of intrinsic clearance for prediction of human hepatic clearance.
    Chao P; Uss AS; Cheng KC
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):189-98. PubMed ID: 20073997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of metabolism of deltamethrin and
    Price RJ; Scott MP; Cantrill C; Higgins LG; Moreau M; Yoon M; Clewell HJ; Creek MR; Osimitz TG; Houston JB; Lake BG
    Xenobiotica; 2021 Jan; 51(1):40-50. PubMed ID: 32757971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs.
    Nikolic K; Agababa D
    J Mol Graph Model; 2009 Oct; 28(3):245-52. PubMed ID: 19713138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
    Ashforth EI; Carlile DJ; Chenery R; Houston JB
    J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of beta-adrenoceptor antagonists as modulators of drug metabolism: effect of lipophilicity on microsomal phase I and II reactions.
    Ahokas JT; Davies C; Ravenscroft PJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):103S-105S. PubMed ID: 6146333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates.
    Shimura K; Murayama N; Tanaka S; Onozeki S; Yamazaki H
    Xenobiotica; 2019 May; 49(5):557-562. PubMed ID: 29808734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in vitro toolbox to accelerate anti-malarial drug discovery and development.
    Charman SA; Andreu A; Barker H; Blundell S; Campbell A; Campbell M; Chen G; Chiu FCK; Crighton E; Katneni K; Morizzi J; Patil R; Pham T; Ryan E; Saunders J; Shackleford DM; White KL; Almond L; Dickins M; Smith DA; Moehrle JJ; Burrows JN; Abla N
    Malar J; 2020 Jan; 19(1):1. PubMed ID: 31898492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro investigation of the hepatic intrinsic clearance of apicidin, a histone deacetylase inhibitor, in mouse, rat, and human, with correction by nonspecific protein binding.
    Shin BS; Park EH; Yoon CH; Kim J; Zee O; Yoo SD
    J Toxicol Environ Health A; 2005 Dec; 68(23-24):2207-18. PubMed ID: 16326434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug.
    Hung DY; Chang P; Cheung K; McWhinney B; Masci PP; Weiss M; Roberts MS
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1079-87. PubMed ID: 12023540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay.
    Berezhkovskiy LM; Khojasteh SC; Halladay JS; Hop CE
    J Pharm Sci; 2009 Jun; 98(6):1922-7. PubMed ID: 18837013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.